Abstract:Background: Infantile spasms (IS) is an age-specific and severe epileptic encephalopathy that occurs in infancy and early childhood and is usually refractory to conventional antiepileptic drugs. Adrenocorticotropic hormone (ACTH) has been the treatment of choice for IS, but ACTH use has been associated with infection and hypertension. Magnesium ion is an N-methyl-D-aspartic acid (NMDA) noncompetitive antagonist that might inhibit NMDA activity and has antiepileptic and neuroprotective effects.Objective: This study compared the efficacy and tolerability of ACTH + magnesium sulfate (MgSO4) versus ACTH monotherapy for the treatment of IS.Methods: This 24-week, randomized, open-label follow-up study enrolled male and female infants with IS. Patients were randomly assigned to receive ACTH 25 U/d + MgSO4 0.25 g/kg/d, or ACTH 25 U/d only (control), intravenously for 3 weeks. Efficacy was assessed over a period of 24 weeks based on seizure frequency, EEG, and Gesell testing of psychomotor skills (subscales: language, motor, adaptive, and personal-social skills; measured using a developmental quotient [DQ]). Tolerability was assessed by monitoring for adverse events using laboratory analysis and clinical evaluation.Results: Thirty-eight infants were enrolled (23 male, 15 female; median age, 9.2 months; 19 patients per group). At 12 weeks, 14 patients (73.7%) who received ACTH + MgSO4 and 9 patients (47.4%) in the control group were seizure free. At 24 weeks, seizure-free rates were 12 (63.2%) in the ACTH + MgSO4 group and 10 (52.6%) in the control group. On EEG, 9 patients (47.4%) in the ACTH + MgSO4 group achieved complete recovery (normalized EEG), 5 (26.3%) attained partial improvement (multifocal spike wave), and 5 (26.3%) had no improvement (hypsarrhythmia or modified hypsarrhythmia). At 4 weeks, in the control group, 5 patients (26.3%) achieved complete recovery, 6(31.6%) achieved partial improvement, and 8(42.1%) had no improvement. Of the 12 patients who were seizure free at 24 weeks in the ACTH + MgSO4 group, 11(91.7%) had complete recovery (normalized EEG); this rate was 7 of 10 (70.0%) in the control group. In the ACTH + MgSO4 group, the change from baseline to 24 weeks in mean (SD) personal-social DQ was significant (from 48.6 [6.4] to 65.2 [7.1], respectively; P < 0.05). In the control group, the difference before and after treatment was nonsignificant (47.7 [6.0] vs 49.9 [4.4]). None of the other Gesell test findings were significant versus baseline. The most common AEs included upper respiratory tract infection and pyrexia (both, 3 [15.8%] per group); diarrhea (2 [10.5%] per group); and hypertension, insomnia, and irritability (all, 0 in the ACTH + MgSO4 group and 2 [10.5%] in the control group). None of the between-group differences in the prevalences of AEs were significant between the 2 groups.Conclusions: In this study in infants with IS, the proportions of patients who were seizure free from 4 to 24 weeks were significantly greater in the ACTH + MgSO4 group compared with the ACTH monotherapy group. Personal-social neurodevelopment was significantly improved from baseline in the group that received combination treatment. Both treatments were generally well tolerated. International Standard Randomized Controlled Trial no. ISRCTN 78654111. (Clin Ther 2010; 32:692-700) (C) 2010 Excerpta Medica Inc.

Adrenocorticotropic hormone therapy alters Q-albumin ratios in patients with infantile epileptic spasms syndrome of unknown etiology

Interictal EEG Based Prediction of ACTH Efficacy in Infantile Epileptic Spasms

[Factors Influencing the Efficacy of Initial Adrenocorticotropic Hormone Therapy for Infantile Epileptic Spasms Syndrome].

Proteomic Analysis of Adrenocorticotropic Hormone Treatment of an Infantile Spasm Model Induced by N-Methyl-d-Aspartic Acid and Prenatal Stress

Evaluation of CSF Albumin Quotient in Neuronal Surface Antibody-Associated Autoimmune Encephalitis

Serum matrix metallopeptidase-9 levels in infantile epileptic spasms syndrome of unknown etiology

Effect of Electroencephalogram Changes in Infantile Spasms Treated with Adrenocorticotropic Hormone

Application of peripheral blood cytokine and immunoglobulin detection in ACTH therapy for the treatment of infantile spasms

Adrenocorticotropic Hormone Combined with Magnesium Sulfate Therapy for Infantile Epileptic Spasms Syndrome: a Real-World Study

Abnormalities in Clostridioides and related metabolites before ACTH treatment may be associated with its efficacy in patients with infantile epileptic spasm syndrome

Immunological markers of drug resistant epilepsy and its response to immunomodulatory therapy with ACTH in children

ACTH Combined LEV Improved EEG and Clincal Symptoms in Children with Cryptogenic Infantile Spasms

The Efficacy and Safety of Different Doses of ACTH Therapy for Infantile Spasms:A Meta-Analysis

Three-week Combination Treatment with ACTH + Magnesium Sulfate Versus ACTH Monotherapy for Infantile Spasms: a 24-Week, Randomized, Open-Label, Follow-Up Study in China.

Integration of Multiscale Entropy and BASED Scale of Electroencephalography after Adrenocorticotropic Hormone Therapy Predict Relapse of Infantile Spasms

Neuroinflammation in Children With Infantile Spasms: A Prospective Study Before and After Treatment With Acthar Gel (Repository Corticotropin Injection)

Crucial involvement of fast waves and Delta band in the brain network attributes of infantile epileptic spasms syndrome

Efficacy and safety of corticosteroids and ACTH in epileptic syndromes beyond Infantile Epileptic Spasms Syndrome (IESS): A systematic review and meta‐analysis

[Effect of Prednisolone and Adrenocorticotropic Hormone in the Treatment of Infantile Spasms: a Meta Analysis].

Hormonal Therapy for Infantile Spasms: A Systematic Review and Meta-Analysis

Clinical effects of low-dose ACTH combined with valproate on infantile spasms